Additional file 2: of Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

Hou, Jian; Jin, Jie; Xu, Yan; Wu, Depei; Ke, Xiaoyan; Zhou, Daobin; Lu, Jin; Du, Xin; Chen, Xiequn; Li, Junmin; Liu, Jing; Gupta, Neeraj; Hanley, Michael; Li, Hongmei; Hua, Zhaowei; Wang, Bingxia; Zhang, Xiaoquan; Wang, Hui; van de Velde, Helgi; Richardson, Paul; Moreau, Philippe

doi:10.6084/m9.figshare.c.3820483_D2.v1

13045_2017_501_MOESM2_ESM.docx (40.33 kB)

Additional file 2: of Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

journal contribution

posted on 2017-07-06, 05:00 authored by Jian Hou, Jie Jin, Yan Xu, Depei Wu, Xiaoyan Ke, Daobin Zhou, Jin Lu, Xin Du, Xiequn Chen, Junmin Li, Jing Liu, Neeraj Gupta, Michael Hanley, Hongmei Li, Zhaowei Hua, Bingxia Wang, Xiaoquan Zhang, Hui Wang, Helgi van de Velde, Paul Richardson, Philippe Moreau

Supplementary results. Hou C16010 China Continuation study J Hematol Oncol. (DOCX 40 kb)

Funding

Millennium Pharmaceuticals Inc.

History

Usage metrics

Keywords

China Ixazomib Multiple myeloma Oral Overall survival Progression-free survival Proteasome inhibitor Relapsed/refractory

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 2: of Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

Funding

Millennium Pharmaceuticals Inc.

History

Usage metrics

Categories

Keywords

Licence

Exports